SBT-272 Improves Mitochondrial Integrity and Motility in Upper Motor Neurons with TDP-43 Pathology

Mukesh Gautam1, Barış Genç1, Ben Helmold2, Janis Kuka2, Marina Makreka-Kuka3, Guozhu Zheng3, Dennis Keefe3, Martin Redmon3, Hatim A. Zariwala3, P. Hande Özdinler1,4*

1Department of Neurology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Ave, Chicago, IL, 60611, USA; 2UOS, Riga, Latvia; 3Stealth BioTherapeutics, Needham, MA; 4Department of Molecular Biosciences, Chemistry of Life Processes Institute, Center for Molecular Innovation and Drug Discovery, Center for Developmental Therapeutics, Northwestern University, Evanston, IL, 60208 USA

Abstract
Mitochondrial dysfunction is a major driver of pathophysiology in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). SBT-272, a CNS penetrant compound that restores mitochondrial inner membrane structure and function under conditions of stress, is an investigational drug in phase I clinical trials. It is a rationally designed small molecule which binds to the mitochondrial phospholipid cardiolipin, preserving mitochondria function against ischemia/reperfusion in cardiac and kidney tissue. SBT-272 was neuroprotective in the SOD1G93A mouse model of ALS (Keefe, et al. NEALS 2019). Since mitochondrial defects emerge as one of the major causes of upper motor neuron (UMN) degeneration with respect to TDP-43 pathology in ALS (Gautam et. al. 2019), we investigated whether SBT-272 would improve mitochondrial integrity and the health of UMN’s exhibiting TDP-43 pathology. Mixed cortical cultures were prepared from prp-hTDP-43A315T-UeGFP mice, in which diseased UMN’s are labeled by eGFP. Cultures were treated with (a) serum free medium, (b) SBT-272 (at 10, 100 and 1000 nM), (c) Edaravone (at 10, 100 and 1000 nM) and (d) a combination of sodium phenylbutyrate (PB, 100 uM) and tauroursodeoxycholic acid (TUDCA, 1 mM), the two components of AMX0035, respectively, for 72 hrs, prior to cellular analyses. SBT-272 significantly improved the structural integrity of mitochondria, enhanced their motility, and resulted in improved UMN axon outgrowth and arborization, indicators of improved neuronal health. While all three test compounds were active to different degrees, the effect of SBT-272 was significantly higher and well differentiated in this assay. The data supports further investigation of SBT-272 as a potential treatment for UMN degeneration in ALS with TDP-43 pathology.

Figure 1: In Vivo Pharmacodynamic effect of SBT-272

(A) Reduction of mitochondrial toxicity in vitro due to induced anoxia in permeabilized cardiac fiber. (B) SBT-272 normalized the plasma creatinine and BUN levels after acute kidney ischemia-reperfusion in vivo. (C) SBT-272 rat brain pharmacokinetics (0.03 to 36 hr) after a single treatment (5 mg/kg, sc). (D) SBT-272 (1.0 mg/kg & 5.0 mg/kg, i.p.) treated for 4 and 24 hours before injury prevented the loss of mitochondrial respiratory control ratio in rat brain following cerebral ischemia-reperfusion injury induced via stereotaxical delivery of 240 µl of ET1 (aSF in sham) in the piriform region. Each data point are oxygraph results (O2K, oxford) of individual animal. ET1 + etoholines-1 vasodilator peptide (* P < 0.05 Kruskal Wallis followed by Dunn’s test, ** P < 0.05 compared to baseline respiration)

Figure 2: CSMN with hTDP-43 pathology can be visualized in prp-hTDP-43A315T-UeGFP mice

Results

SBT-272 had pronounced effect on axon outgrowth of diseased CSMN compared to therapeutically meaningful concentrations

Figure 3: Average axon length and the extent of branching/arborization are outcome measures to quantitatively assess CSMN health

Conclusions
TDP43 inclusions has emerged as the prominent clinical histopathological finding in sporadic ALS and ALS/FTLD patients. It has been shown to directly contribute to upper motor neuron vulnerability with respect to TDP-43 pathology, we demonstrated that SBT-272, which is known to prevent the excess generation of mitochondrial reactive oxygen species (ROS) and to respiration through increased oxidative phosphorylation under conditions of cellular stress, protected and improved neuronal health of CSMN that is diseased due improve mitochondrial to TDP-43 pathology. These data support further investigation of SBT-272 for the potential treatment of motor neurons that become diseased due to TDP-43 pathology.

Figure 4: SBT-272 treatment improved mitochondrial motility in hTDP-43+ CSMN

Future directions / Ongoing work
Based on improvement of diseased UMN’s health and mitochondrial structural integrity by SBT-272 in an in vitro model of ALS, we are encouraged to investigate the effect of SBT-272 in vivo in prp-hTDP-43A315T-UeGFP mouse model of ALS.

Acknowledgements: IPST Montreal for the renal ischemia – reperfusion model in rats.
We thank Northwestern University Center for Advanced Microscopy and Nikon Imaging Center for electron microscopy imaging.

References

Contact:
Hatim Zariwala, PhD, Stealth BioTherapeutics, hatim.zariwala@stealthbiotech.com (631) 697-0698
Hindle Ozdinler, PhD, Department of Neurology, Northwestern University ozdinler@northwestern.edu (312) 503-2774

Figure 5: SBT-272 treatment improves ultrastructural integrity of mitochondria in CSMN that are diseased due to TDP-43 pathology

Figure 6: SBT-272 treatment improves ultrastructural integrity of mitochondria in CSMN that are diseased due to TDP-43 pathology